A Gleiss Lutz team advised Chinese Broncus Holding in connection with its IPO on the Hong Kong Stock Exchange (HKEX) and the related global offering on German law. The issue size is approximately USD 199 million and up to USD 247 million upon full exercise of the over-allotment options.
Broncus is a global market-leading medical technology company focused on the development of interventional pulmonology products. The technology developed by the company addresses weaknesses in existing diagnostic and treatment techniques and the significant unmet medical requirements in connection with lung diseases.
The following Gleiss Lutz team advised Broncus on the German law aspects: Dr Michael Burian (partner, Corporate/M&A), Dr Stephan Aubel (partner, Corporate and Capital Markets, both lead, Frankfurt), Dr Anselm Christiansen, Josefine Wiegand (both Corporate/M&A, Stuttgart), Dr Enno Burk (counsel), Dr Christina Fröb (both Healthcare, Berlin).
Gleiss Lutz has a leading China practice which frequently advises Chinese companies on IPOs and capital market transactions, most recently, for example, Vesync in connection with its IPO in Hong Kong.
Forward
